malaysian healthy ageing societyhealthyageingcongress.com/slides/22/s26_chinszepiaw.pdfmsc as a...
TRANSCRIPT
- 0 - - 0 -
Organised by:
Malaysian Healthy Ageing Society
Co-Sponsored:
- 1 - - 1 -
Overview of Stem Cell Therapy
Chin Sze Piaw MBBS MRCP FNHAM
Consultant Cardiologist, Mawar Medical Centre
Visiting Cardiologist, PPUKM
Clinical and Research Advisor, Cytopeutics
- 2 - - 2 -
Stem Cell Potential
- 3 - - 3 -
Defining Stem Cells
Stem cells are cells that can self-replicate and differentiate
into other specialized cells
- 4 - - 4 -
What is True Stem Cell?
Embryonic stem cell in first 14 days of life
Fetal stem cell divides along 3 germ layers
Unethical
Banned
Causes Cancer
- 5 - - 5 -
Embryonic Stem Cells Can Cause Cancer
- 6 - - 6 -
Stem cells exist in adults to elicit daily repair
The human body recycles itself every 20 years
- 7 - - 7 -
Adult stem cells reside in bone marrow Bone marrow transplant established for 30 years
Bone marrow transplant is essentially haematopoeitic stem
cell (HSC) treatment
- 8 - - 8 -
BMSC for non-haematopoeitic diseases?
- 10 - - 10 -
Mesenchymal Stem/Stromal Cell (MSC)
Differentiates naturally into:
• Adipose Cells
• Osteoblasts
• Cartilage
• Cardiac Muscle
• Smooth Muscle
• Skeletal Muscle
Transdifferentiates into:
•Hepatocytes
• Neurons
• Insulin Producing Cells
• Renal Mesenchyme Cells
- 11 - - 11 -
Differing actions of MSC and PBSC/HSC
HSC/PBSC destroys bone; MSC builds
- 12 - - 12 -
MSC is present in minute numbers but may be rapidly expanded
- 13 - - 13 - Choong, Cheong et al, Cytotherapy 2007
MSC Regenerates New Joint Cartilage
MSC-derived cartilage cells staining for Type II Collagen and still
retaining capacity for replication (arrows)
- 14 - - 14 -
Lee et al, Stem Cells 2007
MSC-HA Saline HA Only
6 wk
12 wk
MSC Regenerates New Joint Cartilage
- 15 - - 15 -
MSC Regenerates Hyaline Cartilage
MSC-HA Saline HA Only
- 16 - - 16 -
MSC can be changed into osteoblast
Wong et al 2008, Pathology
- 18 - - 18 -
MSC for Cardiac Muscle
MSC engrafts and fuses with
damaged heart muscle cells
MSC fuses with Damaged Heart Muscle
- 20 - - 20 -
MSC Repairs Damaged Heart Muscle
MSC replaces disorganized scar tissue in the heart with new cardiomyocyte. Laflamme 2007
- 23 - - 23 -
MSC Forms New Blood Vessels
MSC differentiates into vascular smooth muscle cells for arteriolar formation (“Not just capillary proliferation”)
- 24 - - 24 -
MSC Forms New Blood Vessels
MSC differentiates into vascular smooth muscle cells for artieriolar formation
- 25 - - 25 -
MSC forms the building blocks for musculoskeletal and supporting structures
- 26 - - 26 -
M S C Transdifferentiation - Neuron Induction
Choong, Mok, Cheong, Cytotherapy 2010
- 27 - - 27 -
Functional neurons with neurotransmitter expression
Choong, Mok, Cheong, Cytotherapy 2010
- 28 - - 28 -
IV M S C - Mechanisms of Actions in Stroke
Angiogenesis
Neuron cell regeneration Reduced Scarring
Engraftment
- 29 - - 29 -
MSC hastens recovery from acute renal injury in a mouse model
Wong, Cheong Pathology 2008
- 30 - - 30 -
MSC Cell clusters stain crimson red with dilthizone (for insulin expression)
Wong, Chin 2010
- 31 - - 31 -
TEM confirms increasing secretory granules in induced MSC
Wong, Chin 2010
- 32 - - 32 -
Induced MSC produces insulin in response to different concentrations of glucose stimulation
Insulin Production by induced IPC upon various
glucose stimulation
2.1 2.67 2.83.43
13.63
48.2
0
10
20
30
40
50
60
5.56 16.7 25
Glucose Stimulation (mMol)
Insu
lin C
on
cen
trat
ion
(m
icro
IU/m
L)
Uninduced MSC Induced IPC
M S C For Diabetes
Wong, Chin 2010
- 33 - - 33 -
Proven that our MSC can be differentiated into specialized cell types
MSC
Osteoblast
Chondro-blast
(& NP Cell)
Adipocyte
Arteriole Cardiac
Muscle
Neuron
Insulin (beta islet) cell
- 34 - - 34 -
We Have Successfully Produced True MSC
- 35 - - 35 -
3 days 6 days
12 days (MSC reached confluence) 9 days
Using Proprietary, Animal-free Medium for rapid expansion,…
- 36 - - 36 -
Safe for Clinical Applications
We are able to culture 500 million high quality MSC from just 10-
20 ml BMA within a month for clinical treatment
- 37 - - 37 -
We ensure all cells retain identical characteristics as original
- 38 - - 38 -
All processing in a GMP compliant lab Large clean room 100 facility
Large clean room class 100 for (future expansion)
Laminar air flow
Individualized incubators
Layout (Goods flow and Human flow) according to GMP
ISO 15189 for hematology testing
- 39 - - 39 -
Product Traceability and Safety during storage and transportation
- 40 - - 40 -
On-site Final Preparation
- 42 - - 42 -
ISO 15189, CLEAN ROOM CLASS 100, GMP COMPLIANCE BY BPFK
- 44 - - 44 -
Potential mesenchymal stem cell applications
- 46 - - 46 -
Bone Marrow Cells Are Proven Safe
Autologous Bone-Marrow Derived Stem Cells Are Safe
Meta-analysis of 999 heart failure patients
- 47 - - 47 -
From Atherosclerosis to MI and Heart Failure
Smoking Diabetes HPT Lipid
Inflammation
Endothelial Cell Damage & EPC
Dysfunction
Atherosclerosis & Atherothrombosis
MI/Heart Attack
Scarring
Dilatation & Electrical instability
Heart Failure & Cardiac Arrest
Death
Endothelial Progenitor
Cell (EPC) also
dysfunctional in
cardiovascular patient.
Therefore unable to
repair endothelial cell
damage, leading to
atherosclerosis
Scar tissue is easily
stretched, does not
return to shape. Gives
rise to progressive
heart dilatation and
also electrical
arrhythmias
- 50 - - 50 -
Methodology
(20) Symptomatic (NYHA II-IV)
Severe Dilated Cardiomyopathy (LVEF < 35%)
Suitable for/ likely to benefit from revascularization alone
Suitable for bivent pacing
(10) No.
Assignment
(5) Multivessel disease
Intramyocardial MSC with concurrent CABG
(5) Patent vessels (2) /Non-ischemic (3)
Intracoronary MSC injection alone
(10) Yes.
Plan for revasc (8) or bivent pacing (2) first
Phase IIb Trial. (NMRR Research ID No: 582) 20 patients screened between 2008-2009
•8 patients had significant viable myocardium: sent for revascularization initially
•2 with BBB: sent for consideration of bivent pacing
•5 with ischemic cardiomyopathy
deemed unlikely to benefit from
revascularization alone
•2 had previous and patent vessels
•3 non-ischemic cardiomopathy
- 52 - - 52 -
LV Ejection Fraction
Baseline 6 weeks 3 months 6 months 12 months
Total 26.5 + 6.7 38.6 + 12.8^ 44.5 + 12.3* 47.4 + 7.2* 58.7 + 12.6^
Intracoronary 26.9 + 6.2 33.9 + 6.7 39.6 + 6.3^ 41.7 + 4.1* 47.7 + 2.8^
Intramyocardial 26.1 + 7.8 43.4 + 16.3^ 49.5 + 7.9^ 53.1 + 4.4^ 69.6 + 5.7^
P values when compared to baseline
^ P less than 0.05
* P less than 0.01
Accepted Eur Heart J 2010
Early rapid recovery – Paracrine effect
Late sustained recovery - Regeneration
- 54 - - 54 -
MRI viability study – Intramyocardial injection
Baseline 12 months
Gadolinium delayed enhanced constrast
MRI shows concentric and full thickness
scarring (white area)
Resolution of scar and increased
myocardial thickness with new
myocardium (grey and black areas)
Accepted Eur Heart J 2010
- 55 - - 55 -
Findings corroborated by independent research group
- 56 - - 56 -
REPAIR-AMI: 1 year follow-up
0
5
10
15
20
25
30
35
Death MI HF Hosp PCI Stroke Arrhythmias/Syncope
Placebo BMC
Schachinger et al 2006
- 57 - - 57 -
Patient Population
• 15 patients (Male 4; Female 11)
• Mean age 68 + 12.7 years
• Severe OA
• Significant varus/valgus deformity
• Pain and reduced mobility on NSAIDs or COX2
• Failed multiple hylauronic injections
• No change or worsening OKQ * in previous 6 months
* Oxford Knee Qustionaire
- 59 - - 59 -
Chondrocell in a 3D biodegradable scaffold
MSC as a Single Injection in Severe refractory
osteoarthritis
2-3 mLs injected into knee capsule containing
1-2 million cells per kg body weight
- 62 - - 62 -
Change in Functional Score from baseline
-5 -2 -1 -1 -1
-10 -13
-3 -5
-3 -4
6 3 2
6
6 10
10
-15
-10
-5
0
5
10
15
Prior to Tx 6 mths 12 mths
Major Improvement
Mild Improvement
No Change
Worse
Comparing OKQ scores to baseline
-4 or less: Worse
-3 to 3: No change
4 to 9: mild improvement
10 or more: major improvement
R L
R R L
L
- 63 - - 63 -
MRI independantly reported
• Increased in cartilage
thickness by 40% (noted
in 40%)
• Resolution of
subchondral cysts (noted
in further 10%)
• Reduction in effusion
(noted in further 10%)
Das Gupta, et al (Accepted Int J Rheuamtic Dis 2010)
- 64 - - 64 -
Randomized, prospective, double blind study at
7 leading sports centre in the US,
Single injection
LD 50 million MSC
In biodegradable matrix
55 Patients with moderate-severe OA and torn meniscus
1 WEEK
MSC Effective for OA in a FDA
Multi-Centre Clinical Trial
Method:
Single injection
HD 150 million MSC
In biodegradable matrix
Multiple injection
HA
To assess the safety of an injection of stem cells into the joint capsule and to gain
preliminary efficacy data on the ability of MSC to impact symptomatic improvement, tissue
regeneration and the development of osteoarthritis
- 65 - - 65 -
Superior Pain Reduction by MSC
Normal pain
reduction by
multiple HA inj
is 9-23 pts
only
48
56
28
19
0
10
20
30
40
50
60
All OA Severe OA Patients only
Vis
ua
l A
na
log
ue
Sc
ore
1 Year Magnitude of Pain Reduction by VAS
MSC HA
p=0.05 p=0.004
Effects were dose-dependant and pain scores improved from 6 months to 1 year
implying that an Active Biological Process
MSC group were 3.5 times less likely to experience degenerative bone changes as
compared to multiple HA injections
- 66 - - 66 -
Positive Dose-Response Effect
Severe OA patients only 56
26
19
0
10
20
30
40
50
60
High Dose (150 million) Low dose (50 million) HA
Vis
uA
L A
na
log
ue
Sc
ore
Improvement of Pain from Baseline
No. of Cells Matter
Moderate OA: Min. 50 million cells
Severe OA: Min. 100-150 million cells
- 67 - - 67 -
Bone Marrow Cells (BMC) better than Peripheral Blood Cell (PBC) for Cartilage Repair
Reference: Fei Chang et al, J Orthopaedic Reseach Jan 2008.
Bone Marrow Stem Cells are Superior
- 68 - - 68 -
Comparing regeneration of normal hyaline cartilage with growth factor induced and non-induced MSC
Reference: Gelse 2007
MSC non-induced MSC induced Untreated
- 70 - - 70 -
MSC EPC combination for occlusive PAD
• 62 year old Male
• Diabetes
• Moderate Kidney Failure
• Heart Failure
• Severe Peripheral Artery Disease
• Not suitable for Bypass or angioplasty
• Ulcer on right heel not healing after 2 months
- 71 - - 71 -
* Intensive treatment with topical gels, hyperbaric oxygen and oral medicines and supplements
First presentation
After 1 month intensive
treatment *
3 weeks after intramuscular
Dermacell 1st injection
After 3 months Dermacell
Injection
After 6 months Dermacell
Injection
Deep ischemic non-healing ulcer –
no improvement after 1 month
Ulcer starting to become
smaller, shallow with
healthy bleeding tissue and
overriding fibrin plaque –
derived from new blood
vessel and flow to ulcer
Healed ulcer with no
scarring
MSC EPC combination for occlusive PAD
- 72 - - 72 -
M S C - Nucleus Pulposus Cell Induction
Uninduced MSC
Induction with TGF B
2 wks 4 wks
Collagen II after 4 wks
Proteoglycan Production
evident by metachromatic
staining with Safranin-O
- 73 - - 73 -
L5/S1 IVD Disease 33 year old man
Hyaluron (white appearance) inside disc present at 6 months
- 75 - - 75 -
Clinical Trial of IV MSC for Stroke
- 76 - - 76 -
IV MSC appears feasible and safe and aid recovery after recent stroke
• Barthel Index at baseline, 3,6 and 12 months
• Significant functional recovery (early and sustained).
- 77 - - 77 -
MSC reduces autoimmune reactions THE PARACRINE EFFECT
MSC inhibits T-cell proliferation and activity
- 78 - - 78 -
Role of T-Cells in Autoimmune disease
- 79 - - 79 -
M S C For Autoimmune Disease
M S C from patients with active Rheumatoid Arthritis inhibiting autologous T-cell proliferation and activity
Das Gupta, Wong CY, Chin et al (accepted Int J Rheumatic Dis 2010)
- 80 - - 80 -
M S C Use in Autoimmune Disease
• MSC is Immunoprivileged
• Dampens inflammation and immune reactions
• Demonstrated against GvHD, Crohn’s disease
• Early benefits against MS, Lupus nephritis, T1DM.
• Likely immune-mediated effects in cardiomyopathy, arthritis
Wong, Cheong Cytotherapy 2008
- 81 - - 81 -
NK-DC Cells – not stem cells – are used in cancer
- 82 - - 82 -
World Active Stem Cell Sites
• 200 Stem cell research and therapy centres in 2009
- 83 - - 83 -
Future Directions
• Alternative autologous source (induced pluripotent cell from
skin fibroblast)
• Cell therapy versus tissue engineering
• Best source for off-the-shelf use?
• Wellness and Healthy Aging
- 84 - - 84 -
Conclusions
• Potential in stem cell applications progressively and
consistently demonstrated for MSC
• Safety issues determined by:
• Source
• Ex vivo expansion
• Storage and transport procedures
• Conduct in context of a study with proper informed
consent, patient selection and follow-up
- 85 - - 85 -
Thank You
• Prof Dr Cheong Soon Keng
• Prof Dr S Fadilah Wahab
• A/Prof Dr Leong Chooi Fun
• Dr Then Kong Yong
• Dr Lian QiZhou
• Wong Chee Ying
• Ooi Ghee Hian
- 89 - - 89 -
Who is considered a healthy donor?
• Cancer risk increases with age
• Biotech advances have failed to reduce rate of cancer incidence and mortality
- 90 - - 90 -
Most cancers are due to mutations in adulthoood caused by environmental factors or diet
• Inherited from birth
• Acquired Mutations
• Virus infections
• Radiation exposure
• Contaminants
• Diet
• Smoking
• UV/Sunlight
• Occupational factors
• Alcohol
- 91 - - 91 -
Therefore the healthiest stem cells must be the youngest possible donor - the umbilical cord blood
- 92 - - 92 -
Wharton’s jelly MSC Resilient to hypoxia and tridifferentiation ability
- 93 - - 93 -
Highest proliferative potential seen with UC-MSC compared to adipose tissue and bone marrow
• Note: BMA obtained from 18 patients aged 64-84; adipose tissue
liposuction obtained from 18 patients aged 26-57
• Therefore the differences in proliferative capacity may be due to age
Kern 2006 Stem Cells
- 94 - - 94 -
UC derived MSC is best source for allogeneic stem cell treatment
Highest proliferative capacity
Free from cancer caused by environmental factors
Easy to trace family tree and family medical history
Balance of regenerative potential and paracrine effect
Easy to obtain, expand and store
Same efficacy or better in latest trials
- 95 - - 95 -
Current Status
• Pioneering research on stem cell transdifferentiation (neuron cells, insulin producing cells, immune-modulating cells)
• Developmental work and clinical trials with promising results (safe and efficacious in end-stage heart failure, severe OA,
peripheral arterial occlusive disease)
• Pilot studies for autoimmune disease, neuro diseases
• Bone marrow MSC has best evidence across disciplines
• Autologous source accepted for clinical studies
• Allogeneic MSC - - USE UMBILICAL CORD-DERIVED
• Embryonic and fetal source strictly experimental (major
safety concerns)
• Animal source prohibited
- 96 - - 96 -
Acknowledgements
• Prof Dr Cheong Soon Keng
• Prof Dr S Fadilah Wahab
• A/Prof Leong Chooi Fun
• Dr Then Kong Yong
• Dr Lian QiZhou
• Dr Rebecca Wong Shin Yee
• Wong Chee Yin
• Ng Mei Theng
• Dan Siew Peng
- 101 - - 101 -
Exercise caution!
• Promising use of stem cells for therapies in future
• Understand the disease process
• Understand the rationale for treatment
• Determine the best route for administration
• Part of adjunctive treatment of established options – not an alternative at this stage
• Aware of complications
• To be treated by specialists only in setting of clinical trial
- 102 - - 102 -
Differing actions of PBSC/HSC and MSC
- 103 - - 103 -
• Fracture Repair from cancellous bone chips, demoniralized bone matrix and autogenic bone grafts
• (but not possible with PBSC)
- 104 - - 104 -
Osteogenic potential
- 105 - - 105 -
Differing actions of MSC and PBSC/HSC
HSC/PBSC cause inflammation and healing by fibrosis
MSC regulates inflammatory process and healing through repair
- 106 - - 106 -
MSC from different sources are not the same
Genomic study comparing MSC from bone marrow (BM) with
umbilical cord blood (UCB1 and UCB2):
A. Number of gene sequences shared
B. Concentration of gene expression
- 107 - - 107 -
Using a stranger’s cells has many concerns
RISK OF VIRAL
TRANSMISSION
Some viruses remain latent for up to 10 years. Many new viral diseases
being discovered which is not routinely tested during blood donation
RISK OF
CARCINOGENICITY
Many cancers have familial of genetic link. Therefore potential risk of
genetic transfer by live nucleated cells. A young man may donate stem
cells now and develop cancer 20 years later
RISK OF GENETIC
ABNORMALITY
Few centres also routinely screen for genetic abnormalities which may
manifest later in life
ETHICAL CONCERN
WITH DONOR
Was donation voluntary or was patient coerced? Did donor know cells
used for research or treatment of other patients
LAW VIOLATION No money or inducement can be given to donor.
Donated tissue cannot be bought or sold
QUALITY Cells that has been stored for a long time – is it safe? Do we know what
is expiry date? How many passages of cell multiplication?
COMPATIBILITY How do we check if we are compatible? Not as simple as ABO.
LACK OF EVIDENCE Scarce clinical data on efficacy and safety unlike autologous treatment
Allogeneic BMT associated with 20-30% GvHD
- 108 - - 108 -
MSC is not 100% immunoprivileged